Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced it will present new data on its INTASYL siRNA gene silencing technology at the 10th Immunotherapy of Cancer Conference (ITOC10) in Munich, Germany, from March 21-23, 2024. The technology aims to enhance the effectiveness of immune cells in killing tumor cells, potentially improving cell therapy for hematological malignancies.
March 21, 2024 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals is set to present new data on its INTASYL technology, which could significantly enhance cell therapy for hematological malignancies.
The presentation of new data on INTASYL technology by Phio Pharmaceuticals at a significant conference like ITOC10 highlights the potential advancements in cell therapy for cancer. This could lead to increased investor interest and potentially positive movement in PHIO's stock price in the short term, as the market reacts to the potential of INTASYL to improve cancer treatment outcomes.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90